Journal article

The dendritic cell subtype-restricted C-type lectin Clec9A is a target for vaccine enhancement

Irina Caminschi, Anna I Proietto, Fatma Ahmet, Susie Kitsoulis, Joo Shin Teh, Jennifer CY Lo, Alexandra Rizzitelli, Li Wu, David Vremec, Serani LH van Dommelen, Ian K Campbell, Eugene Maraskovsky, Hal Braley, Gayle M Davey, Patricia Mottram, Nicholas van De Velde, Kent Jensen, Andrew M Lew, Mark D Wright, William R Heath Show all

BLOOD | AMER SOC HEMATOLOGY | Published : 2008

Abstract

A novel dendritic cell (DC)-restricted molecule, Clec9A, was identified by gene expression profiling of mouse DC subtypes. Based on sequence similarity, a human ortholog was identified. Clec9A encodes a type II membrane protein with a single extracellular C-type lectin domain. Both the mouse Clec9A and human CLEC9A were cloned and expressed, and monoclonal antibodies (mAbs) against each were generated. Surface staining revealed that Clec9A was selective for mouse DCs and was restricted to the CD8(+) conventional DC and plasmacytoid DC subtypes. A subset of human blood DCs also expressed CLEC9A. A single injection of mice with a mAb against Clec9A, which targets antigens (Ags) to the DCs, pro..

View full abstract

Grants

Awarded by National Health and Medical Research Council of Australia (Canberra, Australia)


Funding Acknowledgements

We thank V. Milovac, C. Tarlinton, and J. Garbe for assistance with flow cytometry and Prof Akira Shizuo for kindly providing the MyD88- and TRIF-deficient mice.This study was supported by grants 454465, 406660, and 516727 from the National Health and Medical Research Council of Australia (Canberra, Australia), and in part by research funding from CSL Limited (Parkville, Australia).